Viz.ai, a leading AI-powered healthcare company, has received FDA 510(k) clearance for its artificial intelligence algorithm, Viz ICH Plus, which is designed to automate the process of quantifying intracerebral hemorrhage (ICH). The algorithm can accurately identify, label, and measure the volume of segmentable brain structures on non-contrast computed tomography (NCCT) images.
Intracerebral hemorrhage is a type of stroke that accounts for up to 15% of all strokes and has high morbidity and mortality rates. Swift response and accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and planning treatment strategies.
Viz ICH Plus allows radiologists, neurologists, and neurosurgeons to seamlessly incorporate the software into their workflows, automating the manual process of measuring brain bleeds. The algorithm is part of the AI-powered Viz.ai One solution, an enterprise platform that is clinically validated and deployed across more than 1,500 hospitals in the United States. The platform saves time, improves patient outcomes, and increases access to life-saving treatments.
Dr. Peter Kan, professor and chair of the Department of Neurosurgery at the University of Texas Medical Branch, praised the technology, stating that the ability to obtain accurate and quantifiable measurements of intracerebral hemorrhages through Viz ICH Plus significantly enhances the decision-making process. He believes that this technology has the potential to transform how intracerebral hemorrhage cases are approached.
Jayme Strauss, Chief Clinical Officer at Viz.ai, expressed excitement about introducing a product that combines AI capabilities with improved patient outcomes. Viz.ai’s mission is rooted in advancing healthcare through innovation, and Viz ICH Plus exemplifies this dedication.
Viz.ai is the pioneer in using AI algorithms and machine learning to accelerate diagnosis and care for millions of lives across hospitals and health systems in the U.S. and Europe. Their AI-powered Viz.ai One solution is an intelligent care coordination platform that identifies more patients with suspected diseases, informs critical decisions at the point of care, and optimizes care pathways to improve outcomes. The platform delivers significant value to patients, providers, and medical device companies.
In conclusion, Viz.ai’s FDA clearance for its AI algorithm, Viz ICH Plus, marks a significant milestone in the automation of quantifying intracerebral hemorrhage. The technology has the potential to transform how healthcare professionals approach these cases, providing accurate and timely measurements that improve patient outcomes. Viz.ai continues to be at the forefront of using AI to advance healthcare and improve the lives of millions of patients.
